In vitro thrombogenicity of drug-eluting and bare metal stents

Thromb Res. 2020 Jan:185:43-48. doi: 10.1016/j.thromres.2019.11.016. Epub 2019 Nov 14.

Abstract

Aims: We sought to investigate the thrombogenicity of different DES and BMS in an in vitro system of stent perfusion.

Material and methods: The experimental model consisted of a peristaltic pump connected to 4 parallel silicone tubes in which different stents were deployed. Blood was drawn from healthy volunteers and the amount of stent surfaced-induced thrombus deposition was determined using 125I-fibrinogen.

Results: Compared to Resolute, Biomatrix and Vision, Xience was associated with the lowest amount of stent surface-induced thrombus formation, with a significant difference compared to Vision (125I-fibrinogen median value deposition [IQ range]: 50 ng [25-98] versus 560 ng [320-1520], respectively, p < 0.05), but not to other DES. In the second set of experiments Fluoropolymer-coated BMS not eluting drug was associated with a significant 3-fold reduction in 125I-fibrinogen deposition (245 ng [80-300]) compared to Vision (625 ng [320-760], p < 0.05), but a 7-fold increase compared to Xience (35 ng [20-60], p < 0.05). Finally Xience was associated with a significantly greater absorption of albumin compared to BMS.

Conclusions: In an in vitro system of stent perfusion, Xience was associated with the lowest amount of stent surface-induced thrombus formation compared with Resolute, Biomatrix and Vision, with a noted synergistic effect between the fluoropolymer and the drug.

Keywords: Bare metal stent; Drug-eluting stent; Stent thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug-Eluting Stents*
  • Humans
  • Pharmaceutical Preparations*
  • Prosthesis Design
  • Stents / adverse effects
  • Thrombosis* / etiology
  • Treatment Outcome

Substances

  • Pharmaceutical Preparations